LAG3 and melanoma: Ani-PD-1 has been used clinically for several cancers such as melanoma, lung and breast cancer, with evidence of anti-LAG-3 immunotherapeutic blockade efficacy emerging through numerous active cancer treatment clinical trials23,24.